At T2 Biosystems, our mission is to improve sepsis management by empowering clinicians to appropriately treat patients suspected of bloodstream infections faster than ever before. T2 Biosystems accurately identifies pathogenic organisms associated with sepsis in 3 to 5 hours without the wait of blood culture, which can take 1 to 5 or more days. The T2Direct Diagnostics™ suite of products are the first and only FDA-cleared tests that identify sepsis causing pathogens directly from whole blood. Both the T2Bacteria® and T2Candida® Panels are run on the T2Dx® Instrument, and provide meaningful results that may enable changes in clinical outcomes. Assay results provide data to clinicians helping to identify appropriate therapy faster, improve patient outcomes, advance stewardship, and reduce the cost of patient management. T2Biosystems has a strong pipeline of products in development, including the T2ResistanceTM Panel which received “Breakthrough Device” designation from the FDA earlier this year, the T2Lyme® Panel, as well as the T2Candida aurisTM Panel RUO for the direct-from-blood or environmental detection of the deadly superbug, Candida auris.